Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).
Shanghai Fosun Pharmaceutical announced the results of its 2025 second extraordinary general meeting, where the election of an executive director was a key agenda item. The meeting, compliant with relevant legal and corporate governance standards, saw participation from a significant number of shareholders and proxies, with no opposition to the proposed resolutions, indicating strong shareholder support and stable governance.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, focusing on the pharmaceutical industry. It is involved in the development, manufacture, and sale of pharmaceutical products and medical devices, with a significant market presence in China.
Average Trading Volume: 6,907,858
Technical Sentiment Signal: Buy
Current Market Cap: HK$75.52B
For an in-depth examination of 2196 stock, go to TipRanks’ Overview page.